—
C+
C+ The full Closelook — membership. Open the C+ overview

Laboratorios Farmaceuticos ROVI (ROVI.MC) — chart, structure and Closelook read

Home› Indices›
Pick a ticker to load its detail page.

Company snapshot — Laboratorios Farmaceuticos ROVI

ROVI.MC in five paragraphs: what it makes and sells, where it sits in the Closelook stack, who it is priced against, why we track it, what we watch. Research diary, not advice.

What it does
Rovi makes and sells pharmaceutical products across Spain, the EU and other OECD markets, spanning prescription medicines, hospital products such as contrast agents and catheter-care lines, and contract-manufacturing services for injectable drugs including prefilled syringes and vials. It also develops its own molecules, including a low-molecular-weight heparin and newer central-nervous-system treatments. The company was incorporated in 1946 and is headquartered in Pozuelo de Alarcón, Spain, operating as a subsidiary of Norbel Inversiones.
Where it sits in the stack
Rovi carries no seat in our index and sits outside the AI build-out stack; it belongs to the Healthcare sector of our wider universe, where it is tracked as a Spanish specialty and generic drugmaker rather than as part of any compute layer.
Who it is priced against
The diary has no defined peer group for Rovi; the market sometimes compares it with other European specialty and generic drugmakers, such as Grifols, given the shared Spanish base and hospital-product exposure.
Why Closelook tracks it
Rovi holds no index seat and no Closelook score; it does not feature in our editions, and the diary's only current record is its chart reading, tracked as background data rather than a scored constituent.
What the diary watches
Whether the contract-manufacturing side, which ties Rovi to injectable-drug demand from other pharmaceutical companies, shows any shift in order volume that would change how the diary reads its chart pattern.

Laboratorios Farmaceuticos ROVI (ROVI.MC) trades on the MC exchange in Spain.

Written from the company’s public profile and Closelook’s own readings, 2026-09-17. Descriptive, refreshed with the registry; corrections welcome via the imprint. closelook.net is an investment research diary — market structure, index membership and scores are our own readings, not investment advice. Related: index compare · sector dispersion · scanner.

Signals for this name

Every Closelook reading that exists for ROVI.MC, from the same nightly bakes the boards use. Research diary readings, not advice.

Who it is priced against Drug Manufacturers - Specialty & Generic · 8 names with week and year-to-date

Peer group

Drug Manufacturers - Specialty & Generic

This name carries no Closelook score, so its cohort ranks on trend state — distance to the 50- and 200-day averages — never on a score it does not have.

Compared against ROVI.MC on the nightly bakes; the Peers tab ranks the cohort on the Closelook scores where it exists.

Dividends and capital return trailing yield 1.64%, annual · buybacks 55 m EUR in FY2025

Dividends and capital return

What ROVI.MC pays out and buys back — distributions read from the price series, money terms from the filings.

  • Trailing 12 months 0.96 EUR per share · a 1.64% yield on the 2026-09-17 close 1 distribution, paid once a year 2026-09-17
  • Change on the year +2.6% against the prior twelve months prior twelve months 0.94 EUR per share
  • Last distribution 0.96 EUR per share as the price series records it, within days of the ex-date 2026-07-13
  • By calendar year 2025: 0.94 EUR (partial) · 2026: 0.96 EUR to date first distribution recorded in the three-year window: 2025-07-14
  • Dividends paid, FY2025 48 m EUR 27% of earnings
  • Buybacks, FY2025 55 m EUR 1.8% of today's market value
  • Share count −0.2% in FY2025
  • Capital returned 103 m EUR · 85% of free cash flow dividends and buybacks together, against the year’s free cash flow

Per-share amounts are derived from the adjusted price series in the listing currency, so dates sit within days of the ex-date; filing figures come from the fundamentals feed for the last reported fiscal year. An investment diary, not a recommendation.

Weather around the name 3 macro readings: Money Temperature, Factor regime, Sovereign pressure

The weather around this name

Macro readings that apply by membership — the regime, the factor tape, the sector cell, the funding backdrop.

  • Money Temperature Composite 55/100 · S&P 500 fund at 58, above its 50- and 200-day averagesEight instruments scored on position, momentum, volume, volatility and fragility — the regime every name trades inside. Temperature lab → 2026-09-17
  • Factor regime Momentum leading — risk appetite buildingMomentum against low volatility (SPMO / SPLV): above its 50-day trend, 94th percentile of the window, +2.7% over 20 sessions. Factor regime → 2026-09-17
  • Sovereign pressure Index 0.00 · down 0.41 over 21 sessionsG7 long-end yields, 10s30s and the slope — the funding weather for every balance sheet on this site. Sovereign pressure → 2026-09-17

FAQ · from the current data · as of 2026-09-18

Quick answers

What is Laboratorios Farmaceuticos ROVI (ROVI.MC)?

Laboratorios Farmaceuticos ROVI trades as ROVI.MC on the MC exchange (Spain) in the Closelook research universe, as of the registry build of 2026-09-18.

Is ROVI.MC in a Closelook index?

Not currently — Laboratorios Farmaceuticos ROVI is tracked in the Closelook research universe but is not a constituent of a Closelook functional index as of 2026-09-18.

Where does ROVI.MC trade against its moving averages?

Recovery attempt under the 200-day: Trades +0.9% vs the 50-day and -11.2% vs the 200-day average, 31.2% below the 52-week high and +10.9% off the 52-week low; a death cross printed 64 sessions ago. Computed from daily closes. As of 2026-09-17 — a technical state from the nightly Closelook bake, not advice. The Technical tab carries the full row.

What does Laboratorios Farmaceuticos ROVI do?

Rovi makes and sells pharmaceutical products across Spain, the EU and other OECD markets, spanning prescription medicines, hospital products such as contrast agents and catheter-care lines, and contract-manufacturing services for injectable drugs including prefilled syringes and vials. It also develops its own molecules, including a low-molecular-weight heparin and newer central-nervous-system treatments. The company was incorporated in 1946 and is headquartered in Pozuelo de Alarcón, Spain, operating as a subsidiary of Norbel Inversiones. The diary has no defined peer group for Rovi; the market sometimes compares it with other European specialty and generic drugmakers, such as Grifols, given the shared Spanish base and hospital-product exposure.

Where does Laboratorios Farmaceuticos ROVI sit in the AI build-out?

Rovi carries no seat in our index and sits outside the AI build-out stack; it belongs to the Healthcare sector of our wider universe, where it is tracked as a Spanish specialty and generic drugmaker rather than as part of any compute layer. Rovi holds no index seat and no Closelook score; it does not feature in our editions, and the diary's only current record is its chart reading, tracked as background data rather than a scored constituent.

Does Laboratorios Farmaceuticos ROVI pay a dividend?

Laboratorios Farmaceuticos ROVI has paid 0.96 EUR per share over the last twelve months, paid once a year, a trailing yield of 1.64% on the 2026-09-17 close; the last distribution recorded in the price series was 0.96 EUR on 2026-07-13. In fiscal 2025 the company paid 48 m EUR in dividends and bought back 55 m EUR of its own shares, 85% of that year’s free cash flow. The share count fell 0.2% over the fiscal year. The "Dividends and capital return" block on this page carries the lines.

What does this page show?

A live price chart with SMA overlays and drawing tools for ROVI.MC, performance metrics, index-membership context and the Closelook structure read — an investment research diary view, not investment advice.

Related in the Closelook universe

then Drug Manufacturers - Specialty & Generic. Scored names rank on their Closelook score; names without one rank on trend state — above or below their 50- and 200-day averages — never on a score they do not carry.